Cancer Research


Cancer Research Program

Active Protocols by Disease Site

Research Investigators

Isoken Koko, MD, Hematology-Oncology

Nina Yedavalli, MD, Hematology-Oncology

Interim Director of Cancer Research/Research Nurse

Julie Koch, RN, BSN, OCN, CCRP
Phone: (708) 763-2707
Cell: (708) 238-7574
Email: [email protected]

Regulatory Affairs

Carrie Hansen
Phone: (708) 763-2719
Email: [email protected]


Alliance 031501
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally-advanced Urothelial Carcinoma (AMBASSADOR) versus Observation NCT03244384

  • Histologically confirmed muscle-invasive urothelial carcinoma of the bladder or upper tract or Lymph Node + disease
  • Tissue available for central PD-L1 testing
  • Must fit Disease status requirements of the protocol
  • Surgery performed > 4 weeks but < 16 weeks prior to pre-registration
  • No active autoimmune disease or history of immune related diseases
  • No prior PD-1 or PDL-1 therapy
  • ECOG Status 0-2


PreventionAlliance A011401

Breast Cancer Weight Loss Study (BWEL Study) Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer NCT02750826

  • BMI > 27kg/m2 documented within 56 days prior to registration. Most recent BMI must be used for eligibility
  • Self-reported ability to walk at least 2 blocks (at any pace)
  • Histologically confirmed invasive breast cancer and registration must occur within 14 months after the first diagnosis
  • No history of invasive breast cancer in 5 years prior to registration other than the current diagnosis (prior DCIS at any time is acceptable)
  • All adjuvant or neoadjuvant chemotherapy, radiation, and surgery completed at least 21 days prior to registration
  • All subjects must have sentinel lymph node biopsy and/or axillary lymph node dissection
  • Must meet comorbid conditions of the protocol
  • ECOG Status 0 or 1


Learn more about this National Colon Cancer Prevention Trial and read an FAQ to learn more.

PreventionSWOG S0820
Stage 0-IIIA Double-Blind Placebo-Controlled Trial of Eflornithine andSuldinac to Prevent Recurrence of High-Risk Adenomas and Stage 0-III Second Primary Colorectal Cancers in Patients with Colon or Rectal Cancer Phase III-Preventing Adenomas of the Colon with PACES NCT01349881

  • History of Stage 0, I, II or III colon or rectal cancer within 180-456 days of primary resection
  • One year post-op colonoscopy showing no evidence of disease
  • ECOG Status 0-1
  • Must have a pure tone audiometry evaluation to document air conduction within 30 days prior to registration.
  • Must not have documented hx of gastric/duodenal ulcer within 12 months


Quality of Life
Alliance A221504
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opiod Receptor Antagonist in Advanced Non-Small Cell Carcinoma  NCT03087708

  • Advanced Stage IIIB or IV NSCLC
  • ​No known EGFR or EML4-ALK drier mutations
  • Started first-line systemic therapy of MD’s choice within 12 weeks prior to registration, or planning to initiate therapy within 4 weeks after registration.
  • No more than 7 days of prior use of mixed opioid agonist/opioid antagonists within 4 weeks before regostration
  • No methadone within 4 weeks prior to registration
  • Patient must have used opioid medication(s) for pain at some time in the 4 weeks prior to registration
  • ECOG Status 0-2